Capital increase in Onxeo resulting from the exercise of share subscription options from employees

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, has increased its share capital by a nominal amount of €4,357.50 following the issue of 830 shares each with a nominal value of €0.25 and resulting from the exercise of share subscription options from employees of the company.

The new shares were fully paid up in cash. As a result, the total number of shares comprising the capital has increased from 40,544,204 to 40,552,083 and Onxeo’s share capital amounts to €10,138,020.75

150831EN Capital increase